A Comprehensive Patient-Derived Xenograft Collection Representing the Heterogeneity of Melanoma.

Cell Rep 2017 Nov;21(7):1953-1967

Molecular and Cellular Oncogenesis Program, Wistar Institute, Philadelphia, PA 19104, USA. Electronic address:

Therapy of advanced melanoma is changing dramatically. Following mutational and biological subclassification of this heterogeneous cancer, several targeted and immune therapies were approved and increased survival significantly. To facilitate further advancements through pre-clinical in vivo modeling, we have established 459 patient-derived xenografts (PDX) and live tissue samples from 384 patients representing the full spectrum of clinical, therapeutic, mutational, and biological heterogeneity of melanoma. PDX have been characterized using targeted sequencing and protein arrays and are clinically annotated. This exhaustive live tissue resource includes PDX from 57 samples resistant to targeted therapy, 61 samples from responders and non-responders to immune checkpoint blockade, and 31 samples from brain metastasis. Uveal, mucosal, and acral subtypes are represented as well. We show examples of pre-clinical trials that highlight how the PDX collection can be used to develop and optimize precision therapies, biomarkers of response, and the targeting of rare genetic subgroups.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.celrep.2017.10.021DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5726788PMC
November 2017
43 Reads

Publication Analysis

Top Keywords

mutational biological
8
live tissue
8
heterogeneity melanoma
8
tissue resource
4
exhaustive live
4
clinically annotated
4
protein arrays
4
arrays clinically
4
annotated exhaustive
4
resource includes
4
targeted therapy
4
therapy samples
4
resistant targeted
4
samples resistant
4
includes pdx
4
pdx samples
4
sequencing protein
4
characterized targeted
4
patients representing
4
representing full
4

Similar Publications